Navigation Links
Vical Announces News Release and Conference Call Schedule For Third Quarter 2008 Financial Results
Date:10/29/2008

d of the call. For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at info@vical.com.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the company's focus, collaborative partners, product candidates, and developmental status. Risks and uncertainties include whether any product candidates will be shown to be safe and efficacious in clinical trials, the timing of clinical trials, whether Vical or its collaborative partners will seek or gain approval to market any product candidates, the dependence of the company on its collaborative partners, and additional risks set forth in the company's filings with the Securiti
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vical to Present at Upcoming Investor Conferences
2. Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device
3. Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
4. Vical to Present at UBS Global Life Sciences Conference
5. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
6. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
7. Vical to Present at Upcoming Investor Conferences
8. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
9. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
10. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
11. Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015   Cypher Genomics, ... Sequenom, Inc. (NASDAQ: SQNM ), the ... agreement for next generation noninvasive prenatal tests (NIPT). ... interpretation technology, called Mantis™, to advance analysis of ...
(Date:12/24/2014)...  United Therapeutics Corporation (NASDAQ: UTHR ) announced ... has submitted a pre-market approval application to the U.S. ... Medtronic,s SynchroMed ® II implantable drug infusion system ... Therapeutics, Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... GMO corn cases filed across the United States, and ... being consolidated in a Kansas federal court for pretrial proceedings. ... Corn Litigation, MDL No. 2591 in the U.S. District Court ... GMO corn multidistrict litigation (MDL) has been handed over to ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... 27 Alfacell Corporation (OTC Bulletin Board: ACEL) today ... the U.S. Food and Drug Administration (FDA) to discuss ... the ONCONASE rolling New Drug Application (NDA) for the ... the pre-NDA meeting, the FDA provided guidance to the ...
... for Tuesday, February 3, 2009 SAN DIEGO, Jan. 27 ... announced today that the Company will report its fourth ... market closes on Tuesday, February 3, 2009. Neurocrine will ... discuss its financial results and provide a Company update ...
... in Shortest Period of TimeWASHINGTON, Jan. 27 ... in targeted therapies that utilize personalized medicine to ... by the Deloitte Center for Health Solutions found ... to produce a positive return on investment across ...
Cached Biology Technology:Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 3Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 4
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Following the acquisition ... reading feature with the iPhone 5S. It is currently ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB SM ... (GCP) audit to confirm its adherence to current U.S. ... HITLAB to conduct regulated smart device and smart phone ... and research quality. "HITLAB is determined to ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... disorders are almost five times more common among boys than ... $15 million National Institutes of Health (NIH) grant awarded to ... (ACE) research program. Led by principal investigator Kevin ... is part of a $100 million National Institutes of Health ...
... - Influenza outbreaks in the United States typically begin ... spread in seasonal waves across geographic zones. But the ... to the next has baffled scientists. In a ... Obscure Consequence," Elena Naumova, Ph.D., professor of civil and ...
... SAN FRANCISCO, Sept. 6, 2012 -- After last year,s accidental ... State researchers are conducting an elaborate experiment to learn more ... are tagging infected bees with tiny radio trackers, and monitoring ... hive on top of the Hensill Hall biology building on ...
Cached Biology News:Influenza research: Can dynamic mapping reveal clues about seasonality? 2SF State biologists tag 'zombees' to track their flight 2SF State biologists tag 'zombees' to track their flight 3
... Monoclonal Mouse Antibody to Cytokeratin 5 ... is a high molecular weight, basic type ... and the superficial cell layers of stratified ... epithelia and in mesothelial cells and mesothelioma. ...
...
Aldolase A (N-15)...
Bovine Renal Artery Endothelial Cells (BRAEC) (>500,000 cells)...
Biology Products: